Related Experiment Video
Updated: Aug 8, 2026
Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up
Published on: March 26, 2018
CD34 immunophenotyping of blasts in myelodysplasia
1Hämatologische Abteilung, Klinikum Rudolf Virchow, Charlottenburg der Freien Universität Berlin, Germany.
Insights
Immunocytochemistry using CD34 immunotyping improves blast cell identification in myelodysplastic syndromes. This method helps differentiate myelodysplastic syndromes subtypes, aiding diagnosis and prognosis.
Area of Science:
- Hematology
- Immunology
- Oncology
Background:
- Immunofluorescence lacks precision for identifying blast cells in myelodysplasia.
- Immunocytochemistry, particularly the immunoperoxidase technique, offers improved diagnostic capabilities.
Purpose of the Study:
- To evaluate the diagnostic utility of CD34 immunotyping for blast cells in myelodysplastic syndromes (MDS).
- To differentiate between subtypes of MDS, including Refractory Anemia with Excess Blasts (RAEB) and RAEB in Transformation (RAEB-T).
Main Methods:
- Utilized immunoperoxidase technique for CD34 immunotyping of bone marrow cells.
- Analyzed blast cell populations in normal bone marrow, RAEB, and RAEB-T patients.
Main Results:
- Normal bone marrow shows 0.8% CD34 positive type 1 blasts.
- Increased blasts in RAEB are associated with CD34 negative type II and III blasts.
- A distinct population of CD34 positive undifferentiated blasts characterizes RAEB-T and acute myeloid leukemia evolving from MDS.
- CD34 detection aids in distinguishing RAEB from RAEB-T.
Conclusions:
- CD34 immunotyping is a valuable tool for precise blast cell identification in MDS.
- This technique enhances the diagnostic accuracy for classifying MDS subtypes.
- Improved discrimination between RAEB and RAEB-T is achievable with CD34 analysis.
Abstract:
Immunological analysis of bone marrow cells in myelodysplasia using immunofluorescence did not allow accurate morphological identification of blast cells. However, improvement of the immunoperoxidase technique allows one to realize the diagnostic potential of immunocytochemistry. CD34 immunotyping of blasts in normal human bone marrow showed 0.8 +/- 0.4% CD34 positive blasts and these cells had the morphology of type 1 blasts. The increase of bone marrow blasts in RAEB patients is related to CD34 negative type II and III blasts. A clone of undifferentiated CD34 positive blasts is characteristic of RAEB-T and acute myeloid leukaemia evolving from myelodysplasia. The detection of CD34 positive bone marrow blasts allows a better discrimination between RAEB and RAEB-T.
